Workflow
J&J(JNJ) - 2026 Q1 - Quarterly Results
JNJJ&J(JNJ)2025-04-15 12:14

Sales Performance - Total sales for the first quarter of 2025 reached 21,893million,a2.421,893 million, a 2.4% increase compared to 21,383 million in 2024[3] - U.S. sales increased by 5.9% to 12,305million,whileinternationalsalesdecreasedby1.812,305 million, while international sales decreased by 1.8% to 9,588 million[1] - Innovative Medicine segment reported a 2.3% increase in sales, while MedTech segment sales grew by 2.5%[2] - Oncology sales in the U.S. surged by 26.4% to 3,013million,withinternationalsalesincreasingby9.63,013 million, with international sales increasing by 9.6%[10] - The MedTech segment's total revenue for Q1 2025 was 2,103 million, reflecting a 16.4% increase compared to 1,806millioninQ12024[15]−TotalMedTechsegmentsalesreached1,806 million in Q1 2024[15] - Total MedTech segment sales reached 8,020 million in Q1 2025, a 2.5% increase compared to 7,821millioninQ12024[16]−U.S.MedTechsalesgrewby5.17,821 million in Q1 2024[16] - U.S. MedTech sales grew by 5.1% to 4,213 million, while international sales slightly decreased by 0.2% to 3,807million[16]−TheVisionsegmentintheU.S.reporteda3.43,807 million[16] - The Vision segment in the U.S. reported a 3.4% increase in sales, totaling 566 million, while international sales remained relatively flat with a 0.4% increase[16] Profitability - Gross profit decreased by 2.3% to 14,536million,withagrossmarginof66.414,536 million, with a gross margin of 66.4% compared to 69.6% in the previous year[3] - Net earnings for the first quarter of 2025 were 10,999 million, a significant increase of 237.9% from 3,255millionin2024[3]−Adjustednetearningspershare(diluted)roseto3,255 million in 2024[3] - Adjusted net earnings per share (diluted) rose to 2.77, a 2.2% increase from 2.71inthepreviousyear[5]ExpensesandTaxation−Theeffectivetaxrateincreasedto19.32.71 in the previous year[5] Expenses and Taxation - The effective tax rate increased to 19.3% from 12.4% year-over-year[3] - Research and development expenses decreased by 8.9% to 3,225 million, representing 14.7% of sales[3] - The company initiated a restructuring program in the MedTech segment, incurring 55millioninexpensesduringthefirstquarterof2025[6]SegmentPerformance−USsalesintheImmunologysegmentdecreasedby10.555 million in expenses during the first quarter of 2025[6] Segment Performance - US sales in the Immunology segment decreased by 10.5% to 2,196 million, while international sales fell by 15.8% to 1,510million[12]−TheNeurosciencesegmentreporteda8.61,510 million[12] - The Neuroscience segment reported a 8.6% decline in worldwide sales, totaling 1,647 million, with US sales down 8.1% to 968million[13]−Cardiovascular/Metabolism/OthersegmentintheUSsawasignificantincreaseof35.4968 million[13] - Cardiovascular/Metabolism/Other segment in the US saw a significant increase of 35.4%, reaching 855 million, while international sales decreased by 19.7%[14] - XARELTO sales in the US increased by 33.3% to 690million,contributingtoatotalof690 million, contributing to a total of 690 million worldwide[14] - US sales for STELARA decreased by 29.8% to 981million,withinternationalsalesdown38.9981 million, with international sales down 38.9% to 644 million[12] - The Pulmonary Hypertension segment reported a worldwide revenue of 1,025million,adecreaseof2.31,025 million, a decrease of 2.3% from 1,049 million in Q1 2024[13] - SPRAVATO sales in the US increased by 45.0% to 276million,withworldwidesalesreaching276 million, with worldwide sales reaching 320 million, up 41.9%[12] - The company reported a 2.9% decline in US sales for Infectious Diseases, totaling 315million,whileinternationalsalesdecreasedby1.9315 million, while international sales decreased by 1.9% to 487 million[13] Future Projections - Innovative Medicine segment sales for the full year 2024 are projected to reach 2,225million,withsignificantcontributionsfromPulmonaryHypertensionproducts[18]−RybrevantandLazcluzegenerated2,225 million, with significant contributions from Pulmonary Hypertension products[18] - Rybrevant and Lazcluze generated 93 million in total sales in Q1 2024, with U.S. sales accounting for 36million[18]−Talvey′ssalesintheU.S.forQ12024were36 million[18] - Talvey's sales in the U.S. for Q1 2024 were 50 million, with full-year expectations of 241million[18]−OtherOncologyproductsgenerated241 million[18] - Other Oncology products generated 328 million in total sales in Q1 2024, with U.S. sales at 93million[18]−ThecompanyanticipatescontinuedgrowthinthePulmonaryHypertensionsegment,withQ12024U.S.salesof93 million[18] - The company anticipates continued growth in the Pulmonary Hypertension segment, with Q1 2024 U.S. sales of 356 million[18] - International sales of Infectious Diseases products reached 1,395millioninQ12024,withU.S.salesat1,395 million in Q1 2024, with U.S. sales at 19 million[18] - The overall operational growth for the MedTech segment was 4.1%, excluding currency effects[16]